Neurosense Therapeutics Ltd Stock Probability of Future Stock Price Finishing Over 33.73
| NRSNW Stock | USD 0.25 0.13 34.21% |
NeuroSense |
NeuroSense Therapeutics Target Price Odds to finish over 33.73
The tendency of NeuroSense Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 33.73 or more in 90 days |
| 0.25 | 90 days | 33.73 | close to zero percent |
Based on a normal probability distribution, the odds of NeuroSense Therapeutics to move over $ 33.73 or more in 90 days from now is close to zero percent (This NeuroSense Therapeutics Ltd probability density function shows the probability of NeuroSense Stock to fall within a particular range of prices over 90 days) . Probability of NeuroSense Therapeutics price to stay between its current price of $ 0.25 and $ 33.73 at the end of the 90-day period is about 13.59 .
Assuming the 90 days horizon NeuroSense Therapeutics Ltd has a beta of -2.33. This indicates as returns on its benchmark rise, returns on holding NeuroSense Therapeutics Ltd are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, NeuroSense Therapeutics is expected to outperform its benchmark. In addition to that NeuroSense Therapeutics Ltd has an alpha of 4.7011, implying that it can generate a 4.7 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). NeuroSense Therapeutics Price Density |
| Price |
Predictive Modules for NeuroSense Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NeuroSense Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.NeuroSense Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. NeuroSense Therapeutics is not an exception. The market had few large corrections towards the NeuroSense Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NeuroSense Therapeutics Ltd, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NeuroSense Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 4.70 | |
β | Beta against Dow Jones | -2.33 | |
σ | Overall volatility | 0.07 | |
Ir | Information ratio | 0.16 |
NeuroSense Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NeuroSense Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NeuroSense Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| NeuroSense Therapeutics is way too risky over 90 days horizon | |
| NeuroSense Therapeutics has some characteristics of a very speculative penny stock | |
| NeuroSense Therapeutics appears to be risky and price may revert if volatility continues | |
| NeuroSense Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeuroSense Therapeutics Ltd has accumulated about 994 K in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13. | |
| NeuroSense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: NeuroSense Therapeutics Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC Form 6 K - Marketscreener.com |
NeuroSense Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NeuroSense Stock often depends not only on the future outlook of the current and potential NeuroSense Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NeuroSense Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13.6 M | |
| Cash And Short Term Investments | 2.6 M |
NeuroSense Therapeutics Technical Analysis
NeuroSense Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. NeuroSense Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of NeuroSense Therapeutics Ltd. In general, you should focus on analyzing NeuroSense Stock price patterns and their correlations with different microeconomic environments and drivers.
NeuroSense Therapeutics Predictive Forecast Models
NeuroSense Therapeutics' time-series forecasting models is one of many NeuroSense Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary NeuroSense Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about NeuroSense Therapeutics
Checking the ongoing alerts about NeuroSense Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for NeuroSense Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| NeuroSense Therapeutics is way too risky over 90 days horizon | |
| NeuroSense Therapeutics has some characteristics of a very speculative penny stock | |
| NeuroSense Therapeutics appears to be risky and price may revert if volatility continues | |
| NeuroSense Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeuroSense Therapeutics Ltd has accumulated about 994 K in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13. | |
| NeuroSense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: NeuroSense Therapeutics Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC Form 6 K - Marketscreener.com |
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.